Table 3 Baseline characteristics of ALD patients in the phase II cohort study (n = 1,184).

From: Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study

 

Without colonic neoplasia (n = 619)

With CRA

(n = 541)

With CRC

(n = 24)

P value

Age, years

53 (15)

54 (14)

64 (13)

<0.001

Male, n (%)

578 (93)

526 (97)

15 (92)

0.007

Liver cirrhosis, n (%)

98 (16)

113 (21)

16 (67)

<0.001

alcohol intake amount (g/day)

57 (70)

69 (69)

108 (81)

0.007

Current or ex-smoker, n (%)

431 (74)

427 (81)

23 (96)

0.002

AFP (ng/mL)

3.0 (1.2)

3.0 (1.9)

3.9 (1.8)

0.647

Albumin (g/dL)

4.4 (0.5)

4.4 (0.6)

3.6 (1.0)

<0.001

Bilirubin (mg/dL)

1.1 (0.6)

1.1 (0.6)C

1.0 (0.6)

0.777

AST (U/L)

33 (26)

34 (25)

30 (17)

0.372

ALT (U/L)

35 (34)

36 (31)

22 (16)

0.023

GGT (U/L)

100 (92)

103 (98)

104 (74)

0.587

Platelet count, x109/L

219 (75)

222 (83)

150 (79)

0.006

Prothrombin time (INR)

1.02 (0.10)

1.01 (0.09)

1.07 (0.23)

0.005

CRC T stage (Tis/1/2/3/4/x)

  

8/3/2/9/1/1

 
  1. Continuous variables are expressed as the median (interquartile range) and categorical variables are presented as numbers (%).
  2. P values were calculated by one-way ANOVA test and χ2 test for continuous and categorical variables, respectively.
  3. AFP, Alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRA, colorectal adenoma; CRC, colorectal cancer; GGT, gamma-glutamyl transferase; INR, international normalized ratio.
Back to article page